Risk Assessment for Companies purchasing Dossiers without doing actual F & D

Pharmaceutical companies often purchase ready-to-file dossiers (including formulation, analytical, stability, and bioequivalence data) to accelerate product launches and reduce R&D costs. While this approach can deliver commercial advantages, it introduces substantial risks across regulatory, operational, legal, and business domains. Key…













